These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30390673)

  • 1. Cerebrospinal fluid pro-inflammatory cytokines differentiate parkinsonian syndromes.
    Starhof C; Winge K; Heegaard NHH; Skogstrand K; Friis S; Hejl A
    J Neuroinflammation; 2018 Nov; 15(1):305. PubMed ID: 30390673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume of Interest Analysis of Spatially Normalized PRESTO Imaging to Differentiate between Parkinson Disease and Atypical Parkinsonian Syndrome.
    Sakurai K; Imabayashi E; Tokumaru AM; Ito K; Shimoji K; Nakagawa M; Ozawa Y; Shimohira M; Ogawa M; Morimoto S; Aiba I; Matsukawa N; Shibamoto Y
    Magn Reson Med Sci; 2017 Jan; 16(1):16-22. PubMed ID: 27001391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Manual MRI morphometry in Parkinsonian syndromes.
    Möller L; Kassubek J; Südmeyer M; Hilker R; Hattingen E; Egger K; Amtage F; Pinkhardt EH; Respondek G; Stamelou M; Möller F; Schnitzler A; Oertel WH; Knake S; Huppertz HJ; Höglinger GU
    Mov Disord; 2017 May; 32(5):778-782. PubMed ID: 28150443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MR findings in the substantia nigra on phase difference enhanced imaging in neurodegenerative parkinsonism.
    Sugiyama A; Sato N; Kimura Y; Ota M; Maekawa T; Sone D; Enokizono M; Murata M; Matsuda H; Kuwabara S
    Parkinsonism Relat Disord; 2018 Mar; 48():10-16. PubMed ID: 29279191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy.
    Constantinides VC; Paraskevas GP; Stamboulis E; Kapaki E
    Neurol Sci; 2018 Feb; 39(2):359-364. PubMed ID: 29196955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study.
    Compta Y; Dias SP; Giraldo DM; Pérez-Soriano A; Muñoz E; Saura J; Fernández M; Bravo P; Cámara A; Pulido-Salgado M; Painous C; Ríos J; Martí MJ;
    Parkinsonism Relat Disord; 2019 Aug; 65():3-12. PubMed ID: 31178335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early strong intrathecal inflammation in cerebellar type multiple system atrophy by cerebrospinal fluid cytokine/chemokine profiles: a case control study.
    Yamasaki R; Yamaguchi H; Matsushita T; Fujii T; Hiwatashi A; Kira JI
    J Neuroinflammation; 2017 Apr; 14(1):89. PubMed ID: 28438224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
    Yoshita M; Hayashi M; Hirai S
    Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Chougar L; Faouzi J; Pyatigorskaya N; Yahia-Cherif L; Gaurav R; Biondetti E; Villotte M; Valabrègue R; Corvol JC; Brice A; Mariani LL; Cormier F; Vidailhet M; Dupont G; Piot I; Grabli D; Payan C; Colliot O; Degos B; Lehéricy S
    Mov Disord; 2021 Feb; 36(2):460-470. PubMed ID: 33137232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI evaluation of progressive supranuclear palsy: differentiation from Parkinson's disease and multiple system atrophy.
    Eraslan C; Acarer A; Guneyli S; Akyuz E; Aydin E; Colakoglu Z; Kitis O; Calli MC
    Neurol Res; 2019 Feb; 41(2):110-117. PubMed ID: 30373485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusivity of cerebellar hemispheres enables discrimination of cerebellar or parkinsonian multiple system atrophy from progressive supranuclear palsy-Richardson syndrome and Parkinson disease.
    Nicoletti G; Rizzo G; Barbagallo G; Tonon C; Condino F; Manners D; Messina D; Testa C; Arabia G; Gambardella A; Lodi R; Quattrone A
    Radiology; 2013 Jun; 267(3):843-50. PubMed ID: 23329659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism.
    Chougar L; Arsovic E; Gaurav R; Biondetti E; Faucher A; Valabrègue R; Pyatigorskaya N; Dupont G; Lejeune FX; Cormier F; Corvol JC; Vidailhet M; Degos B; Grabli D; Lehéricy S
    Mov Disord; 2022 Jun; 37(6):1245-1255. PubMed ID: 35347754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
    Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
    J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
    Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
    J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.